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Abstract
Objective: The valved conduit Contegra (bovine jugular vein) has being implanted for more than
7 years in the right ventricular outflow tract and it is noted that the available reports have been
mixed. The aim of this study is to review the reported evidence in the literature.
Methods: Search of the relevant literature for the primary endpoints of operative mortality and
morbidity and secondary endpoints of follow-up haemodynamic performance including severe
stenosis, regurgitation and need for reintervention are presented.
Results: We selected and analysed 17 series including 767 patients. Commonest indication was
Fallot's tetralogy. Operative mortality was 2.6%. Operative morbidity was 13.9%. In follow-up, the
incidence of intraconduit stenosis was 10.9% (incidence of stenosis for the 12 millimetre conduit
was 83.3% in one series) and that of at least moderate regurgitation was 6.3%.
The aspirin users had a stenosis incidence of 10.5% compared to the non-users had a stenosis
incidence of 9.6%.
Conclusion:  A dissent on the performance of the Contegra is discussed, while results are
satisfactory in the majority of studies apart for the smallest conduits (12 and 14 millimetre),
suggesting an association to compromised run-off. The role of aspirin as antithrombotic modulator
remains controversial.
Introduction
The refinement of congenital cardiac surgical procedures
requiring reconstruction of the right ventricular outflow
tract (RVOT) (or substitution for the autograft pulmonary
valve in Ross procedure) has led to an increased need for
valved conduits, especially for neonates and small infants.
The haemodynamic performance and long-term compli-
cations of xenograft, composite grafts and homografts
have been far from ideal. In view of the rising demand for
conduits (especially of small internal diameter) and the
decrease in homograft availability, alternative options
have been sought.
A new solution popularised in Europe and of late in the
USA and Canada is a valved conduit xenograft, the Conte-
gra (formerly Venpro, Medtronic Inc, Minneapolis, MN,
USA). Derived from bovine jugular vein, it incorporates
the native tri-leaflet valve and a natural sinus. The prosthe-
sis is preserved in buffered low concentration glutaralde-
hyde in order to maintain the leaflet flexibility. Contegra
conduits are availble with internal diameter of
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12,14,16,18, 20 and 22 millimeters (mm). Theoretical
advantages include structural continuity and 'off-the-
shelf' availability. An inherent feature of the Contegra is
the fact that being derived from the venous circulation
and has the morphological characteristics of a 'vascular'
valved conduit under conditions of low pressure similar
to the pulmonary vascular tree (and not the higher pres-
sure and hemodynamic condition of the systemic circula-
tion). Therefore its use is not licenced for the left
ventricular outflow tract.
A number of studies have reported on this conduit. It
appears that some surgeons are concerned with its per-
formance, while others are satisfied. In order to draw
some further practical conclusions, we have systematically
reviewed the literature in order to assess the existing
cumulative peri-operative data and postoperative per-
formance.
Methods
Ethical issues were not raised, therefore ethical approval
was not sought. No conflict of interest is declared.
We performed a literature search (PubMed) for studies
reporting on Contegra, published between 1965 and 31
March 2007): Searching keyword was "Contegra" limited
to "human subjects." Articles were also identified using
the function "related articles" in PubMed and cross-vali-
dated by hand search. No language restrictions were
applied.
We performed summary descriptive statistics on pooled
data:Primary outcomes discussed were surgical mortality
and morbidity and secondary outcomes as follow-up
haemodynamic performance including: intra-conduit
pressure difference recordings, severe conduit stenosis
and regurgitation as also need for reintervention. Special
care was given to include data on conduit specific reinter-
vention incidence during the follow-up period. Postoper-
ative aspirin strategy was also assessed. Denominators
were related to actual data. Missing data were not
defaulted. Where follow-up data were sought, we opted
for a period prevalence denominator of patient-years and
haemodynamic assessment was extracted focusing at the
time point of measurement. Due to inherent heterogene-
ity we did not attempt statistical inference.
Data and analysis
We identified and considered 22 publications [1-22]. Five
of them included data from others [2] from [13,3] from
[14] and [15,6] from [16,11] from [19] with apparently
overlapping cohorts, so we utilized data from the largest
ones [2,3,6,11].
Two papers from the same country [2,6] presented equal
number of subjects with partially overlapping periods of
observation. The units where surgery took place were not
stated in either. The rest of their data being dissimilar, we
concluded that the two series had to be entered to the
database separately and that the same number of patients
appears plainly a coincidence.
Thus we accumulated data from 17 series [1-12,17,18,21-
23].
Results
1. Demographics And Pathologies
Data from 767 patients were reported in total in these 17
studies (ranging from 6 to 108 per study). Each patient
received a single Contegra with the exception of two case
that had two each [1,20].
Mean age was 7.6 years (range 2 days-55 years). Mean
weight was 23.1 Kg (range 2.8–125 Kg). The commonest
indications for implantation of Contegra was Fallot's
Tetralogy (198 patients), Arterial Trunk (Truncus, 91
patients), Ross procedure (80 patients), Pulmonary
Atresia (50 patients), Double Outlet/Inlet Right Ventricle
(40 patients), Transposition of Great Arteries (29
patients).
2. Operative Outcomes
We sought the standardised surgical outcomes according
to published guidelines[23].
Mortality
There were 20 deaths reported in 766 operations. The
cumulative Mortality was thus 2.6%.
Morbidity
Morbidity is presented in Table 1. Morbidity data were
individually and clearly reported in 8 series with 330
patients [[3-5,8,10-12] and [23]]: 46 patients suffered one
or more of 54 complications. Cumulative operative mor-
bidity was thus calculated to 13.9%.
3. Follow-Up
584 patients had being followed up for 22 months in
average (range 1–56) rending the total calculated follow-
up to 573 patient-years.
Echocardiography was utilised for routine interval follow-
up.
Severe Stenosis and timepoint of follow-up is presented in
Table 2.Journal of Cardiothoracic Surgery 2008, 3:62 http://www.cardiothoracicsurgery.org/content/3/1/62
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Average pressure differences (commonly yet erroneously
[24] termed 'gradient') were: peak 17 mm Hg (millimetres
of Mercury) (range 8.5–27) and mean 8.2 mmHg (range
7–13). Incidence of intraconduit stenosis, was 10.9%
necessitating 56 interventional and 28 surgical proce-
dures.
Routine postoperative aspirin administration was explic-
itly stated in six series [2,5,9,17,21,22]. The authors of
another series [4] reported adding post discharge aspirin
empirically in neonates (10 mg/day till the patient reaches
5–6 Kg of body weight) after two thrombotic events in
their cohort. Routine aspirin administration is not men-
tioned in the other series.
The aspirin users had a stenosis incidence of 10.5%. The
non-users had a stenosis incidence of 9.6%.
Regurgitation-Insufficiency(Table 3)
Incidence of at least moderate regurgitation was 6.3% as
assessed by echocardiography in standardised methodol-
ogy[25].
Discussion
Quality control in surgery motivates to good operative
outcomes [21] but also to long-term results, particularly
in surgery for congenital heart disease. We have some-
times seen a 'euphoric' description of operative results but
disappointing long-term outcome.
A dissent on the performance of the Contegra is noted:
The titles of three of the largest series [1,2,20] were contra-
dictory: direct unequivocal negative message in the first
[that was debated strongly in discussion by the audience
[1] and enthusiasm in the other two [2,20]. Meyns [1] had
apparently stopped utilizing Contegra! The difference in
opinions may be partially explained by the heterogeneity
of the series, as expected from an intervention applicable
to premature neonates as well as adults for a constellation
of indications.
The experience of Meyns is isolated and rather baffling! If
it is excluded, the results are encouraging overall but the
follow-up is short. The reason for the high incidence of
distal stenosis in Meyns' group remains obscure although
the non-use of aspirin may contribute.
The few data on pressure differences are exemplary for the
limited data available for all prostheses in vivo. We have
to insist that the ubiquitous term 'pressure gradient' is
inaccurate when measured in units of pressure and was
perceived as pressure difference [24].
The definition of graft stenosis is extremely varying (espe-
cially if taken into account the large number of young
children where low gradient has a completely different
significance than in an adult): higher stenosis rate has
been shown in smaller- size patients and conduits.
Echocardiography for estimation of pressure difference is
the most common technique since it is easy to apply and
relatively of low cost. However, having a large number of
complex defects, the question of specificity and sensitivity
is important.
Having a relative low number of patient-years of follow-
up could reflect a high mid-term mortality or incomplete
follow-up data dies.
A contentious issue is that of post discharge aspirin [[1],
see pages 838–40]. (Table 2). Out of the present data, a
conclusive answer to whether aspirin prevents graft
thrombosis and stenosis is rather difficult. A definitive
conclusion would require a randomised prospective trial
in order to avoid confounding biases. The feasibility and
the ethics of such a study are however also debatable, in
the light of the experience of Tiete [4]. It appears reasona-
ble to 'aspirinise' the recipients of Contegra in the absence
of contraindications given the known prophylactic value
of aspirin in small conduits as coronary bypass.
The choice of the internal diameter of conduit is related to
the anatomy and size of the patient (table 4). Most sur-
geons agree that the largest possible diameter conduit
should be utilised. It is impressive that the incidence of
stenosis in the smallest 12 mm conduit was 83.3% in one
trial with diligent follow-up of two years[1]. Interrupted
suture line could be considered as a potential solution to
Table 1: Contegra™ 1999–2007- perioperative complications
Type Number of incidents
Bleeding 5
Neurological 3
Sepsis 4
Respiratory 13
Thrombosis 2
Renal 2
Cardiac 13
Other 12
Total 54Journal of Cardiothoracic Surgery 2008, 3:62 http://www.cardiothoracicsurgery.org/content/3/1/62
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Table 2: Contegra™ 1999–2007, follow-up pressure difference and anticoagulation strategy, re-interventions in detail
reference N peak ΔP in mmHg mean ΔP in mmHg Anticoagulation strategy Percutaneous Surgical Total Reinterventions
[1] 55 unknown unknown nil 17 5 22
[2] 67 17 8 aspirin for 6 months 2 1 3
[3] 100 18 unknown nil 0 4 4
[4] 29 unknown unknown Aspirin until weighing 5–6 
kg
21 3
[5] 20 unknown 13 ± 4.8 Heparinisation and aspirin 0 0 0
[6] 67 unknown 11 nil 0 1 1
[7] 30 unknown nil 0 2 2
[8] 15 11.1 ± 4.5 nil 0 0 0
[9] 6 8.5 24.5 ± 13.1 aspirin for 3 months max 0 5 5
[10] 40 'increased' in 2- unknown 
otherwise
nil 0 3 3
[11] 38 unknown nil 0 0 0
[12] 12 unknown 12.9 ± 12.3 nil 6 3 9
[17] 60 unknown aspirin for 6 months 6 1 7
[21] 62 unknown 14 aspirin for 3 months 0 0 0
[18] 76 unknown aspirin 4 0 4
[22] 78 23 unknown Heparinisation and aspirin 19 2 21
56 28 84
N: number of patients followed-up
ΔP: Pressure Difference, commonly reported as 'gradient'
Hg: Mercury
PA: pulmonary artery(-ies)Journal of Cardiothoracic Surgery 2008, 3:62 http://www.cardiothoracicsurgery.org/content/3/1/62
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the distal anastomotic stenosis but is obviously upon to
surgeon's preference to apply this technique due to
increased risk of bleeding.
Complications were also commoner in double outlet
right ventricle and pulmonary atresia, possible because of
variable run-off in distal pulmonary vasculature. The
excellent results reported on a series of 20 Ross procedures
[5], where the run-off at the normal pulmonary vessels is
assumed universally good.
Conclusion
A dissent on the performance of the Contegra is noted:
This lack of consensus regarding the best conduit for
RVOT reconstruction reflects the fact that no "perfect"
solution is available.
It is important to formulate an evidence- base opinion on
the available technologies and we hope that our review
will address this.
Limitations of the study
Although every effort was made to extract data that can be
pooled and tabulated, the heterogeneity of demographics,
casemix and reporting studies performed in different insti-
tutions, with different methodologies, populations and
time frames was considered an obstacle in inferential sta-
tistics; therefore we report descriptive statistics. Compari-
son between the groups was difficult, especially as data on
conduit sizes were missing from the largest series in par-
ticular.
We understand that the heterogeneity data may be inter-
preted in a number of ways equally valid to the one the
authors chose here.
Table 3: Contegra™ 1999–2007: postoperative moderate or severe regurgitation/insufficiency in conduit
Reference Number Degree Of Regurgitation/Insufficiency
III(moderate) III-IV(moderate to severe) IV (severe)
10 9
20
41 0
50
60
80
10 0
11 0
70 3
12 0
17 13 3
21 0
20 0
21 12
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